TERC and colorectal carcinoma: To date, several approaches have successfully targeted TERC in CRC through the use of antisense oligonucleotides (ASOs) [261], RNA interference (RNAi) [262,263], and small-molecule scaffolds (i.e., GRN163L/imetelstat and CX-5461) [263,264].